FTC Secures Record $12 Million HSR Penalty in Edwards/Genesis Settlement

What Happened

According to U.S. Federal Trade Commission (Press Release, July 13, 2026) on July 13, 2026 in Federal — FTC / DOJ Antitrust, The Federal Trade Commission obtained a record $12 million in penalties from Edwards Lifesciences Corp. and Genesis MedTech Group Ltd. to settle allegations that the parties structured and closed a 2024 acquisition in a manner that avoided Hart-Scott-Rodino Act premerger review. The settlement is the largest of its kind and signals aggressive enforcement of HSR filing rules on deal structuring. The primary source is linked in the Source section below; readers are encouraged to review it directly for full context.

Why This Is Trending Now

The size of the penalty resets the risk calculus on aggressive deal structuring intended to slip under the HSR threshold and puts every mid-market M&A team on notice.

Why Businesses Should Pay Attention

Boards, GCs, and deal counsel must document HSR analysis, avoid staged structures designed to evade filing, and expect the agencies to scrutinize side letters, options, and earnouts that shift when control actually transfers.

Practical Considerations

Businesses may want to monitor the status of the underlying rule, filing, proceeding, or announcement as it evolves. Companies may need to evaluate how this development could interact with current contracts, licenses, disclosures, and compliance programs. The issue may raise questions around vendor obligations, reporting timelines, and internal policy updates that warrant discussion with qualified counsel.

Cogent Law Perspective

Cogent Law supports corporate clients on HSR analysis, staged acquisitions, and antitrust-facing deal documentation — including how to design earnouts and options that do not create avoidance risk. The best next step is to speak with counsel about the facts specific to your organization.

Key Takeaways

• The size of the penalty resets the risk calculus on aggressive deal structuring intended to slip under the HSR threshold and puts every mid-market M&A team on notice.
• Boards, GCs, and deal counsel must document HSR analysis, avoid staged structures designed to evade filing, and expect the agencies to scrutinize side letters, options, and earnouts that shift when control actually transfers.
• Cogent Law supports corporate clients on HSR analysis, staged acquisitions, and antitrust-facing deal documentation — including how to design earnouts and options that do not create avoidance risk.
• Review the primary source from U.S. Federal Trade Commission (Press Release, July 13, 2026) for the full record before making any decisions.
• Speak with Cogent Law to discuss how this development may affect your business.

Related Practice Areas